European Heart Journal Advance Access originally published online on November 25, 2005
European Heart Journal 2005 26(24):2733-2741; doi:10.1093/eurheartj/ehi673
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology
1Members of the Board of the European Society of Cardiology
2Representatives of ESC Working Group 27 Acute Cardiac Care
3Representatives of ESC Working Group 10 Interventional Cardiology
Received 2 November 2005; accepted 10 November 2005; online publish-ahead-of-print 25 November 2005.
* Corresponding author: Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besançon, France. Tel: +33 381 668 539; fax: +33 381 668 582. E-mail address: jean-pierre.bassand{at}ufc-chu.univ-fcomte.fr
Abstract
Summary Reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) is the most important component of treatment, as it strongly influences short- and long-term patient outcome. The main objective of healthcare providers should be to achieve at least 75% of reperfusion therapy applied to patients suffering from STEMI in a timely manner, and preferably within the first 3 h after onset of symptoms.
Establishing networks of reperfusion at regional and national level, implying close collaboration between all the actors involved in reperfusion therapy, namely hospitals, departments of cardiology, PCI centres, emergency medical systems (EMS), (para)medically staffed ambulances, private cardiologists, primary care physicians, etc., is a key issue. All forms of reperfusion, depending on local facilities, need to be available to patients. Protocols must be written and agreed for the strategy of reperfusion to be applied within a network. Early diagnosis of STEMI is essential and is best achieved by rapid ECG recording and interpretation at first medical contact, wherever this contact takes place (hospital or ambulance). Tele-transmission of ECG for immediate interpretation by experienced cardiologists is an alternative.
Primary PCI is the preferred reperfusion option if it can be performed by experienced staff within 90 min after first medical contact. Thrombolytic treatment, administered if possible in the pre-hospital setting, is a valid option if PCI cannot be performed in a timely manner, particularly within the first 3 h following onset of symptoms. Thrombolysis is not the end of the reperfusion therapy. Rescue PCI must be performed in the case of thrombolysis failure. Next-day PCI after successful thrombolysis has been proven efficacious.
Quality control is important for monitoring the efficacy of networks of reperfusion. All elements that influence time to reperfusion must be taken into account, particularly transfer delays, in-hospital delays, and door-to-balloon or door-to-needle times. The rate of reperfusion achieved must also be taken into consideration.
Professional organizations such as the European Society of Cardiology (ESC) have the responsibility to impart this message to the cardiology community, and inform politicians and health authorities about the best possible strategy to achieve reperfusion therapy.
Key Words: Myocardial infarction • Reperfusion therapy • Primary PCI
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Wienbergen, J. Senges, and A. K. Gitt Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill? Diabetes Care, February 1, 2008; 31(Supplement_2): S222 - S225. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bravo Vergel, S. Palmer, C. Asseburg, E. Fenwick, M. de Belder, K. Abrams, and M. Sculpher Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis Heart, October 1, 2007; 93(10): 1238 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Faxon Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Current State of ST-Elevation Myocardial Infarction Care Circulation, July 10, 2007; 116(2): e29 - e32. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Widimsky, D. Bilkova, M. Penicka, M. Novak, M. Lanikova, V. Porizka, L. Groch, M. Zelizko, T. Budesinsky, M. Aschermann, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial Eur. Heart J., March 2, 2007; 28(6): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Huynh, J. O'Loughlin, L. Joseph, E. Schampaert, S. Rinfret, M. Afilalo, S. Kouz, B. Cantin, M. Nguyen, M. J. Eisenberg, et al. Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study Can. Med. Assoc. J., December 5, 2006; 175(12): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mandelzweig, A. Battler, V. Boyko, H. Bueno, N. Danchin, G. Filippatos, A. Gitt, D. Hasdai, Y. Hasin, J. Marrugat, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004 Eur. Heart J., October 1, 2006; 27(19): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Danchin Should intravenous thrombolysis keep a place in the treatment of acute ST-elevation myocardial infarction? Eur. Heart J., May 2, 2006; 27(10): 1131 - 1133. [Full Text] [PDF]
|
|